Literature DB >> 26941128

Hepatocyte growth factor and alternative splice variants - expression, regulation and implications in osteogenesis and bone health and repair.

Rachel N Frisch1, Kevin M Curtis1,2, Kristina K Aenlle1, Guy A Howard1,2,3.   

Abstract

INTRODUCTION: Bone marrow-derived mesenchymal stem cells (MSCs) can differentiate into multiple cell types, including osteoblasts, chondrocytes, and adipocytes. These pluripotent cells secrete hepatocyte growth factor (HGF), which regulates cell growth, survival, motility, migration, mitogenesis and is important for tissue development/regeneration. HGF has four splice variants, NK1, NK2, NK3, and NK4 which have varying functions and affinities for the HGF receptor, cMET. HGF promotes osteoblastic differentiation of MSCs into bone forming cells, playing a role in bone development, health and repair. AREAS COVERED: This review will focus on the effects of HGF in osteogenesis, bone repair and bone health, including structural and functional insights into the role of HGF in the body. EXPERT OPINION: Approximately 6.2 million Americans experience a fracture annually, with 5-10% being mal- or non-union fractures. HGF is important in priming MSCs for osteogenic differentiation in vitro and is currently being studied to assess its role during bone repair in vivo. Due to the high turnover rate of systemic HGF, non-classic modes of HGF-treatment, including naked-plasmid HGF delivery and the use of HGF splice variants (NK1 & NK2) are being studied to find safe and efficacious treatments for bone disorders, such as mal- or non-union fractures.

Entities:  

Keywords:  Bone; HGF; Hepatocyte Growth Factor; Osteoblastic Differentiation; Osteoblasts; Osteoclasts; cMET

Mesh:

Substances:

Year:  2016        PMID: 26941128      PMCID: PMC5031543          DOI: 10.1517/14728222.2016.1162293

Source DB:  PubMed          Journal:  Expert Opin Ther Targets        ISSN: 1472-8222            Impact factor:   6.902


  85 in total

1.  Functional map and domain structure of MET, the product of the c-met protooncogene and receptor for hepatocyte growth factor/scatter factor.

Authors:  Ermanno Gherardi; Mark E Youles; Ricardo N Miguel; Tom L Blundell; Luisa Iamele; Julian Gough; Abhishek Bandyopadhyay; Guido Hartmann; P Jonathan G Butler
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-03       Impact factor: 11.205

2.  Regulation of hepatocyte growth factor expression by NF-κB and PPARγ in adipose tissue.

Authors:  Jun Yin; Jong Han Lee; Jin Zhang; Zhanguo Gao; Vsevolod Y Polotsky; Jianping Ye
Journal:  Am J Physiol Endocrinol Metab       Date:  2014-02-25       Impact factor: 4.310

3.  Hepatocyte growth factor and its actions in growth plate chondrocytes.

Authors:  R M Grumbles; D S Howell; L Wenger; R D Altman; G A Howard; B A Roos
Journal:  Bone       Date:  1996-09       Impact factor: 4.398

4.  Human bone marrow-derived stem cell proliferation is inhibited by hepatocyte growth factor via increasing the cell cycle inhibitors p53, p21 and p27.

Authors:  Ketian Chen; Carlos Perez-Stable; Gianluca D'Ippolito; Paul C Schiller; Bernard A Roos; Guy A Howard
Journal:  Bone       Date:  2011-08-30       Impact factor: 4.398

5.  The p38 MAPK pathway is essential for skeletogenesis and bone homeostasis in mice.

Authors:  Matthew B Greenblatt; Jae-Hyuck Shim; Weiguo Zou; Despina Sitara; Michelle Schweitzer; Dorothy Hu; Sutada Lotinun; Yasuyo Sano; Roland Baron; Jin Mo Park; Simon Arthur; Min Xie; Michael D Schneider; Bo Zhai; Steven Gygi; Roger Davis; Laurie H Glimcher
Journal:  J Clin Invest       Date:  2010-06-14       Impact factor: 14.808

6.  Kiss-1 suppresses MMP-9 expression by activating p38 MAP kinase in human stomach cancer.

Authors:  Kyung Hee Lee; Jae-Ryong Kim
Journal:  Oncol Res       Date:  2009       Impact factor: 5.574

7.  An alternatively processed mRNA generated from human hepatocyte growth factor gene.

Authors:  K Miyazawa; A Kitamura; D Naka; N Kitamura
Journal:  Eur J Biochem       Date:  1991-04-10

8.  Results of a double-blind, placebo-controlled study to assess the safety of intramuscular injection of hepatocyte growth factor plasmid to improve limb perfusion in patients with critical limb ischemia.

Authors:  Richard J Powell; Michael Simons; Farrel O Mendelsohn; George Daniel; Timothy D Henry; Minako Koga; Ryuichi Morishita; Brian H Annex
Journal:  Circulation       Date:  2008-06-16       Impact factor: 29.690

9.  Blocking c-Met signaling enhances bone morphogenetic protein-2-induced osteoblast differentiation.

Authors:  Seiji Shibasaki; Sachie Kitano; Miki Karasaki; Sachi Tsunemi; Hajime Sano; Tsuyoshi Iwasaki
Journal:  FEBS Open Bio       Date:  2015-04-20       Impact factor: 2.693

10.  Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor.

Authors:  L Naldini; K M Weidner; E Vigna; G Gaudino; A Bardelli; C Ponzetto; R P Narsimhan; G Hartmann; R Zarnegar; G K Michalopoulos
Journal:  EMBO J       Date:  1991-10       Impact factor: 11.598

View more
  7 in total

1.  Hepatocyte growth factor administration increases bone soluble phosphate and alters bone chemical structure in diabetic hypertensive rats.

Authors:  Kamal Awad; Natasha G Boyes; Ramlah Iqbal; Mohamed Ahmed; Adel Mohamed; Pranesh Aswath; Corey R Tomczak; Venu Varanasi
Journal:  J Mater Res       Date:  2021-07-23       Impact factor: 2.909

2.  Combinations of growth factors for human mesenchymal stem cell proliferation and osteogenic differentiation.

Authors:  Veronika Hefka Blahnova; Jana Dankova; Michala Rampichova; Eva Filova
Journal:  Bone Joint Res       Date:  2020-08-19       Impact factor: 5.853

Review 3.  Recent Advances in Monoclonal Antibody Therapy for Colorectal Cancers.

Authors:  Kyusang Hwang; Jin Hwan Yoon; Ji Hyun Lee; Sukmook Lee
Journal:  Biomedicines       Date:  2021-01-05

Review 4.  Multinucleated Giant Cells: Current Insights in Phenotype, Biological Activities, and Mechanism of Formation.

Authors:  Kourosh Ahmadzadeh; Margot Vanoppen; Carlos D Rose; Patrick Matthys; Carine Helena Wouters
Journal:  Front Cell Dev Biol       Date:  2022-04-11

5.  Hepatocyte growth factor is a potential biomarker for osteoproliferation and osteoporosis in ankylosing spondylitis.

Authors:  L Torres; E Klingberg; M Nurkkala; H Carlsten; H Forsblad-d'Elia
Journal:  Osteoporos Int       Date:  2018-10-10       Impact factor: 4.507

Review 6.  The Potential Role of Hepatocyte Growth Factor in Degenerative Disorders of the Synovial Joint and Spine.

Authors:  Hitoshi Tonomura; Masateru Nagae; Ryota Takatori; Hidenobu Ishibashi; Tomonori Itsuji; Kenji Takahashi
Journal:  Int J Mol Sci       Date:  2020-11-18       Impact factor: 5.923

7.  Elevated serum level of hepatocyte growth factor predicts development of new syndesmophytes in men with ankylosing spondylitis.

Authors:  Anna Deminger; Eva Klingberg; Merja Nurkkala; Mats Geijer; Hans Carlsten; Lennart T H Jacobsson; Helena Forsblad-d'Elia
Journal:  Rheumatology (Oxford)       Date:  2021-04-06       Impact factor: 7.580

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.